SCHEMBL6487587

SCHEMBL6487587

COc1ccc(Cl)cc1C(Cl)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
NPSR1 Q6W5P4 3/20 0.51
L3MBTL1 Q9Y468 3/20 0.51
LMNA P02545 3/20 0.48
MAPT P10636 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
ALPL P05186 1/20 0.46
ALPI P09923 1/20 0.46
ALPG P10696 1/20 0.46
ALOX12 P18054 1/20 0.46
HTT P42858 1/20 0.46
LPAR1 Q92633 1/20 0.44
CNR2 P34972 1/20 0.43
SLC6A2 P23975 5/20 0.43
SLC6A4 P31645 5/20 0.43
SLC6A3 Q01959 5/20 0.43
CYP2D6 P10635 1/20 0.43
IDO1 P14902 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24353670 0.84 SCN4A (0.47) ALDH1A1NPSR1L3MBTL1LMNAMAPT
SCHEMBL18496496 0.82 IDO1 (0.55) ALDH1A1NPSR1L3MBTL1MAPTTDP1
SCHEMBL10712718 0.82 CNR2 (0.56) ALDH1A1NPSR1L3MBTL1LMNAMAPT
SCHEMBL6487591 0.80 PDE1B (0.43) ALDH1A1NPSR1L3MBTL1LPAR1CNR2
SCHEMBL10709535 0.78 NPSR1 (0.44) ALDH1A1NPSR1L3MBTL1LMNAMAPT
SCHEMBL10798581 0.77 SCN4A (0.42) ALDH1A1NPSR1L3MBTL1LMNAMAPT
SCHEMBL9231158 0.77 LMNA (0.50) ALDH1A1NPSR1L3MBTL1LMNAMAPT
SCHEMBL9228033 0.76 NPSR1 (0.54) ALDH1A1NPSR1L3MBTL1LMNAMAPT
SCHEMBL23748311 0.76 GAA (0.51) ALDH1A1NPSR1L3MBTL1LMNAMAPT
SCHEMBL9228936 0.75 ALDH1A1 (0.50) ALDH1A1NPSR1L3MBTL1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6933322-B2 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2005-08-23 US disclosed
US-20030216442-A1 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus WYETH 2003-11-20 US disclosed
EP-0149077-B1 (3-ARYL-2,3-DIHYDROBENZOFURAN-3-YL)ALKYLAMINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1988-09-21 EP disclosed
US-4602035-A Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1986-07-22 US disclosed
EP-0149077-A1 (3-Aryl-2,3-dihydrobenzofuran-3-yl)alkylamines, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1985-07-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216442-A1 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus INSR, GPR119, SLC5A1 ALDH1A1 648/4885NPSR1 714/4885L3MBTL1 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.